BESANÇON, France--(BUSINESS WIRE)--Pixee Medical, world leader in augmented reality navigation technologies for orthopedic surgery, takes a major step forward in its expansion with a $15 million capital raising. This transaction, led by Relyens Innovation Santé, UI Investissement, Innovacom, Angelor and Bpifrance will enable Pixee Medical to accelerate its development in the United States and launch its next generation of innovative products..

BESANÇON，法国——（商业新闻短讯）——Pixee Medical是整形外科增强现实导航技术的世界领导者，通过1500万美元的融资，在其扩张方面迈出了重要一步。此次交易由Relyens Innovation Santé、UI Investisement、Innovacom、Angelor和Bpifrance牵头，将使Pixee Medical加速其在美国的发展，并推出下一代创新产品。。

'We are extremely proud of the success of this capital raising. This investment is a significant step forward in our expansion in the US, which is a strategic market for our company. It will enable us to reinforce our technological leadership by developing new products for augmented surgeons, who will benefit from the latest advances in immersive technologies, connectivity, and artificial intelligence; all in the service of their patients.', emphasizes Sébastien Henry, CEO of Pixee Medical..

“我们为此次融资的成功感到无比骄傲。这项投资是我们在美国扩张的重要一步，美国是我们公司的战略市场。它将使我们能够通过为增强外科医生开发新产品来加强我们的技术领先地位，增强外科医生将受益于沉浸式技术，连通性和人工智能的最新进展；都是为病人服务的。”，Pixee Medical首席执行官Sébastien Henry强调。。

The capital we have raised will play a key role in Pixee Medical's growth strategy, which focuses on four major objectives:

我们筹集的资金将在Pixee Medical的增长战略中发挥关键作用，该战略侧重于四个主要目标：

To significantly strengthen its presence in the United States with the opening of a subsidiary in the first quarter.

通过在第一季度开设子公司，大大加强其在美国的业务。

To rapidly deploy our new range of augmented reality navigation platforms.

快速部署我们新的一系列增强现实导航平台。

To expand our presence in Asia by opening an office in Singapore.

通过在新加坡开设办事处来扩大我们在亚洲的业务。

To recruit new talents to support our growth.

招募新人才以支持我们的发展。

The success of this capital raising underscores not only the investors' confidence in Pixee Medical's potential, but also the company's commitment to remaining at the forefront of technological innovation in the area of navigation solutions for orthopedic surgery.

此次融资的成功不仅突显了投资者对Pixee Medical潜力的信心，也突显了该公司在骨科手术导航解决方案领域保持技术创新前沿的承诺。

Since the company was founded in 2018, Pixee Medical has grown rapidly by marketing disruptive solutions:

自2018年公司成立以来，Pixee Medical通过营销颠覆性解决方案迅速发展：

Knee+: A navigation solution for total knee replacement integrating an augmented reality glasses and instruments that are both minimally invasive and reusable. Already marketed worldwide thanks to CE certification and FDA 510(k) clearance; more than 5,000 patients around the world have already benefitted from this unique solution.

膝关节+：全膝关节置换的导航解决方案，集成了增强现实眼镜和微创和可重复使用的仪器。由于CE认证和FDA 510（k）许可，已经在全球销售；全世界已有5000多名患者从这种独特的解决方案中受益。

Clinical studies have validated the precision and effectiveness of this technology, which is perfectly suited to the requirements of customized implant positioning. Thus, this unique solution meets the needs of the growing ambulatory surgery centers..

临床研究已经验证了该技术的精度和有效性，它非常适合定制种植体定位的要求。因此，这种独特的解决方案满足了不断增长的门诊手术中心的需求。。

Shoulder+: A mixed-reality navigation solution specifically designed for total shoulder replacement achieved worldwide success in 2023, when it obtained CE mark certification in accordance with MDR regulation. FDA approval is anticipated by the end of the year for access to the US target market.

肩部+：一种专门为全肩置换设计的混合现实导航解决方案于2023年取得了全球成功，当时它根据MDR法规获得了CE标志认证。预计FDA将于年底批准进入美国目标市场。

Pixee Medical will be showcasing its latest technological advances at the AAOS World Arthroplasty Congress, which will be held February 12 to 16, 2024 at the Moscone Center in San Francisco.

Pixee Medical将在2024年2月12日至16日在旧金山莫斯科内中心举行的AAOS世界关节成形术大会上展示其最新技术进步。

The company expresses its gratitude to its investors for their continued support and looks forward to this promising new chapter in its ongoing commitment to medical excellence and to improving the quality of life for patients.

该公司对投资者的持续支持表示感谢，并期待着这一充满希望的新篇章，继续致力于医疗卓越和改善患者的生活质量。

'We have been with Pixee since the company was founded in Bourgogne-Franche-Comté, and have witnessed its transition from a pioneer to a global supplier of guidance solutions for orthopedic surgery. We are convinced that this new round of financing will enable Pixee Medical to maintain its role as world technology leader, conquer a fast-growing market, facilitate surgical procedures for orthopedic surgeons, and ensure better patient care', adds Guillaume Blanchet, Investment Director at UI Investissement..

“自从Pixee公司在勃艮第-弗朗奇公司成立以来，我们一直与Pixee合作，见证了它从骨科手术指导解决方案的先驱转变为全球供应商。UI Investissement投资总监纪尧姆·布兰切特（GuillaumeBlanchet）补充道：“我们相信，这一新一轮融资将使Pixee Medical保持其作为世界技术领导者的角色，征服快速增长的市场，促进整形外科医生的外科手术，并确保更好的患者护理。”。。

'As a long-standing partner of Pixee Medical, we are delighted to continue our support of the company in the development of its data-centric platform and innovative orthopedic products, particularly for patients requiring shoulder and hip replacement', states Bervin Bouani, Investment Director at Turenne Capital..

Turenne Capital投资总监Bervin Bouani表示：“作为Pixee Medical的长期合作伙伴，我们很高兴继续支持该公司开发以数据为中心的平台和创新的骨科产品，特别是针对需要肩关节和髋关节置换的患者。”。。

'Pixee Medical has a promising pipeline, and its flagship product, Knee+ for total knee replacement, addresses the limitations of current robotic-assisted surgery systems, thanks to its technology that enables orthopedic surgeons to perform precise surgeries with a clear benefit for patients while adapting to the surgeons' practice', said Jean-François Morin, Investment Director at Bpifrance, a new investor in Pixee Medical..

“Pixee Medical拥有一条很有前途的管道，其旗舰产品膝关节+全膝关节置换术解决了当前机器人辅助手术系统的局限性，这要归功于它的技术，它使整形外科医生能够进行精确的手术，同时为患者带来明显的好处，同时适应外科医生的“实践”，Bpifrance投资总监Jean-Francois Morin说，Pixee Medical的新投资者。。

About Pixee Medical

关于Pixee Medical

Pixee Medical develops augmented reality solutions for implant placement, that offer orthopedic surgeons’ cutting-edge tools for precise and efficient intervention. Its first product has been used in over 5,000 procedures in more than 20 countries, for example, the United States, Australia, India, and several European countries, thus demonstrating its positive impact on surgical practices worldwide..

Pixee Medical开发用于植入物植入的增强现实解决方案，为整形外科医生提供尖端工具，以进行精确有效的干预。其首款产品已在20多个国家（例如美国，澳大利亚，印度和几个欧洲国家）的5000多个程序中使用，从而证明了其对全球外科实践的积极影响。。

About the investors

关于投资者

Bpifrance:

Bpifrance：

Bpifrance's equity investments are implemented by Bpifrance Investissement. Bpifrance finances companies at every stage of their development, whether through loans, guarantees or equity capital. Bpifrance supports companies in their innovation projects and international projects. Bpifrance also supports their export activities with a wide range of products.

Bpifrance的股权投资由Bpifrance Investissement实施。无论是通过贷款、担保还是股权资本，法国都在公司发展的每个阶段为其提供资金。Bpifrance支持公司的创新项目和国际项目。Bpifrance还通过多种产品支持其出口活动。

Consulting, training, matchmaking, and acceleration programs for start-ups, SMEs, and ETIs are also part of the Bpifrance offering for entrepreneurs. Thanks to Bpifrance and its 50 regional branches, entrepreneurs benefit from a close, unique, and efficient contact to help them meet their challenges..

针对初创企业、中小企业和ETI的咨询、培训、配对和加速计划也是Bpifrance为企业家提供的服务的一部分。多亏了Bpifrance及其50个地区分支机构，企业家们从紧密、独特和高效的联系中受益，帮助他们应对挑战。。

For further information: https://www.bpifrance.fr/

For further information: https://www.bpifrance.fr/

Relyens Innovation Santé (Turenne Capital):

Relyens Innovation Santé（Turenne Capital）：

Founded in May 2014, Relyens Innovation Santé is an investment structure specializing in healthcare innovation capital. It is controlled and owned by the Relyens Group, a mutual insurance company specializing in risk management for healthcare, social, and medical players. Advised by Turenne Santé (the health division of the Turenne Group), Relyens Innovation Santé's mission is to support the growth and development of innovative companies in the healthcare sector..

Relyens Innovation Santé成立于2014年5月，是一家专门从事医疗创新资本的投资机构。它由Relyens Group控制和拥有，Relyens Group是一家专门为医疗保健、社会和医疗参与者进行风险管理的互助保险公司。由Turenne Santé（Turenne Group的健康部门）担任顾问，Relyens Innovation Santé的使命是支持医疗保健领域创新公司的成长和发展。。

Turenne Groupe, one of France's leading private equity firms, has a 25-year track record of helping entrepreneurs innovate, grow, and transfer their businesses. An independent player, the group manages assets worth €1.7 billion. With over €300 million under management, our healthcare team (Turenne Santé) invests across the entire value chain of healthcare companies, using a variety of investment approaches..

Turenne Group是法国领先的私人股本公司之一，在帮助企业家创新、成长和转移业务方面有25年的历史记录。作为一个独立的参与者，该集团管理着价值17亿欧元的资产。我们的医疗团队（Turenne Santé）管理着3亿多欧元，通过各种投资方式投资于医疗保健公司的整个价值链。。

For further information: https://www.relyens.eu/fr / www.turennecapital.com

For further information: https://www.relyens.eu/fr / www.turennecapital.com

Innovacom:

Innovacom：

A specialist in deeptech and industry, INNOVACOM supports the launch and development of technology start-ups that contribute to environmental, digital, and industrial transitions in a wide range of sectors (energy, telecommunications, mobility, smart cities, aeronautics, new space, etc.). An investment company integrated into the Turenne Group since 2018, INNOVACOM and its teams are present in Paris, Lyon, and Marseille.

INNOVACOM是deeptech和工业领域的专家，支持技术初创公司的启动和发展，这些初创公司有助于广泛领域（能源、电信、移动、智能城市、航空、新空间等）的环境、数字和产业转型。INNOVACOM是一家自2018年加入Turenne集团的投资公司，其团队目前在巴黎、里昂和马赛。

INNOVACOM has invested over €1billion, supported more than 300 technology and industrial start-ups, including 6 unicorns, participated in more than 20 IPOs, and has carried out more than 150 strategic divestitures to major players..

INNOVACOM投资超过10亿欧元，支持了300多家科技和工业初创企业，其中包括6家独角兽，参与了20多家IPO，并对主要参与者进行了150多次战略性资产剥离。。

For further information: www.innovacom.com

更多信息：www.innovacom.com

Angelor:

Angelor：

Founded in 2008, Angelor is an independent venture capital company based in Lyon, with a mission to 'develop finance that serves the common good'. Now recognized for the quality of its shareholders and the companies it finances, Angelor has brought together over 250 shareholders, most of whom are experienced business leaders committed to financing and supporting innovative entrepreneurs in their sector.

Angelor成立于2008年，是一家总部位于里昂的独立风险投资公司，其使命是“发展为公共利益服务的金融”。Angelor因其股东和融资公司的素质而备受赞誉，目前已聚集了250多名股东，其中大多数是经验丰富的商业领袖，致力于为其所在行业的创新创业者提供融资和支持。

Angelor has invested nearly €30 million in 76 start-ups, particularly in the healthcare, agri-food, and environmental sectors – helping to create over 700 direct jobs, mainly in the Auvergne-Rhône-Alpes region..

Angelor在76家初创企业中投资了近3000万欧元，特别是在医疗保健、农业食品和环境部门，帮助创造了700多个直接就业岗位，主要是在奥弗涅-罗恩-阿尔卑斯地区。。

For further information: https://angelor.fr/

更多信息：https://angelor.fr/

UI Investissement:

UI投资：

UI is an independent company specializing in the development of unlisted French companies. For over 50 years, UI has been committed to working alongside the managers of growing SMEs and ETIs to create and develop companies that are economically and sustainably successful. UI Investissement manages nearly €1.5 billion in assets and invests in 300 managers.

UI是一家专门从事未上市法国公司开发的独立公司。50多年来，UI一直致力于与成长中的中小企业和ETI的管理人员合作，创建和发展经济上可持续成功的公司。UI Investissement管理着近15亿欧元的资产，并投资了300名管理人员。

UI Investissement invests in Burgundy Franche Comté thanks to the Invest Création 5.0 and OSER BFC funds supported by the European Regional Development Fund..

UI投资勃艮第Franche Comté感谢投资创造5.0和欧洲区域发展基金支持的大胆BFC基金。。

For further information: www.ui-investissement.fr

更多信息：www.ui-investissement.fr